---
title: First-in-human study of naporafenib (LXH254) with or without spartalizumab
  in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
date: '2023-12-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38039779/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231202170737&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Naporafenib, with or without spartalizumab, showed an acceptable
  safety profile, pharmacodynamic activity and limited antitumor activity. Additional
  naporafenib combination therapies are currently under ...'
disable_comments: true
---
CONCLUSIONS: Naporafenib, with or without spartalizumab, showed an acceptable safety profile, pharmacodynamic activity and limited antitumor activity. Additional naporafenib combination therapies are currently under ...